Huperzine A - Neuro-Hitech/Xel

Drug Profile

Huperzine A - Neuro-Hitech/Xel

Alternative Names: HupA transdermal; Qian-ceng-ta transdermal; XEL 001HG; XEL 001HP

Latest Information Update: 26 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Guangzhou Xiangxue Pharmaceuticals; Neuro-Hitech; Xel Pharmaceuticals
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 26 Mar 2010 Huperzine A transdermal is in active development
  • 11 Sep 2008 Xel Pharmaceuticals completes preclinical development of a prototype huperzine A, once-weekly, transdermal patch for Alzheimer's disease in USA
  • 11 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top